

The prognostic value of estimated albumin excretion rate compared with urine albumin/creatinine ratio for

adverse cardiovascular outcomes among patients with chronic kidney disease

Lucie Bauer¹, Insa E. Emrich¹, John W. Pickering², Kathrin Untersteller¹, Franziska Sandermann¹, Kyrill S. Rogacev¹, Sarah Seiler¹, Danilo Fliser¹, Gunnar H. Heine¹

¹Internal Medicine IV - Nephrology and Hypertension; Saarland University Medical Center, Homburg

²University of Otago, Department of Medicine, Christchurch, New Zealand



Background / Hypotheses

- 24 h measured albumin excretion is used as gold standard for quantifying albuminuria but it is considered to be too cumbersome for clinical practice.
- ➤ KDIGO guidelines recommend using the albumin-creatinine ratio (ACR) in spot urine samples.
- However, ACR underestimates 24 h albumin excretion in muscular individuals.
- Equations were recently developed that adjust ACR for muscle mass surrogates (sex, age, ethnicity) and yield an "estimated albumin excretion rate" (eAER).
- The prognostic implication of substituting eAER for ACR is unknown,

Methods/Results

- As ongoing prospective cohort study, CARE FOR HOMe recruited 444 patients with CKD G 2 G 4 between 2008 and 2012.
- ACR was quantified from a morning spot urine sample and eAER was calculated according to the Ellam equation (Box).
- Patients were classified in KDIGO albuminuria categories.
- 379 patients had complete three year follow-up for cardiovascular events (pre-defined as acute myocardial infarction, stroke, amputation above the ankles, any surgical or interventional coronary/cerebrovascular or peripheral-arterial revascularization, or death of any causes).

Ellam Equation for Estimated Creatinine Excretion Rate

 $eCER_{Ellam} (mg/d) =$

Male/black: $1413.9 + (23.2 \text{ x age}) - (0.3 \text{ x age}^2)$

Female/black: $1148.6 + (15.6 \text{ x age}) - (0.3 \text{ x age}^2)$

Male/nonblack: $1307.3 + (23.1 \text{ x age}) - (0.3 \text{ x age}^2)$

Female/nonblack: $1051.3 + (5.3 \text{ x age}) - (0.1 \text{ x age}^2)$

Estimated albumin excretion rate $(mg/d) = ACR (mg/mg) * eCER_{Ellam} (mg/d)$

Box: Ellam equations for eCER and eAER

Methods/Results

1		Total cohort	CVE event	No CVE event	p
	Age (years)	66 ± 12	71 ± 9	64 ± 13	< 0.001
)	Gender (female)	148 (39 %)	25 (31 %)	123 (41 %)	0.075
	Body mass index (kg/m²)	30 ± 5	30 ± 5	30 ± 5	0.362
	Diabetes mellitus (yes)	148 (39 %)	43 (52 %)	105 (35 %)	0.007
	Systolic blood pressure (mmHg)	154 ± 24	154 ± 24	153 ± 26	0.889
5	Diastolic blood pressure (mmHg)	87 ± 13	81 ± 13	88 ± 12	< 0.001
ì	Smoking (yes)	35 (9 %)	9 (11 %)	26 (9 %)	0.522
	Prevalent CVD (yes)	122 (32 %)	55 (67 %)	67 (23 %)	< 0.001
	LDL-Cholesterol (mg/dl)	117 ± 36	107 ± 33	120 ± 36	0.005
	Cholesterol (mg/dl)	193 ± 43	178 ± 39	197 ± 43	< 0.001
-	Phosphorus (mg/dl)	3.4 ± 0.7	3.5 ± 0.7	3.4 ± 0.7	0.075
	Albuminuria (mg/g)	40 (8 –193)	66 (22 – 316)	32 (7 – 152)	0.298
	CRP (mg/l)	2.8 (1.2 –5.4)	4.0 (1.8 – 9.2)	2.6 (1.1 – 4.8)	0.061

Table 1: Baseline characteristics of CARE FOR HOMe participants. Indicated are mean ± standard deviation, or patient numbers (percentages). Because of skewed distribution, albuminuria and CRP are given as median (interquartile range).

- NRI_{events} and $NRI_{non-events}$ were calculated for the reclassification to different albuminuria categories by eAER *versus* ACR.
- 82 patients suffered a cardiovascular event during the three year follow-up time
- 12 out of these 82 patients were re-classified to a higher AU category, and only one patient to a lower AU category.
- > NRI_{event} 13,4% (CI 95%: 5.2 to 21.6)
- 297 patients had no CVE during FU
- 13 out of these 297 patients were reclassified to a higher, and two patient to a lower AU category.
- NRI_{no event} -3,7% (CI 95%: -8.2 to -1.2)

Results

		Events		No events			
		eAER		eAER			
		A1	A2	A3	A1	A2	A3
	A1	21 (26%)	9 (11%)	0	141 (48%)	6 (2%)	0
ACR	A2	0	27 (33%)	3 (4%)	2 (1%)	87 (30%)	7 (2%)
	A3	0	1 (1%)	21 (26%)	0	0	54 (18%)
		$NRI_{event} = 13.4\%$ (5.2 to 21.6)			$NRI_{noevent} = -3.7\%$ (-8.2 to -1.2)		

Table 2: Reclassification matrices for CARE FOR HOMe participants with and without CVE (patients reclassified to a more advanced AU category are given in red, and patients reclassified to a less advanced AU category in yellow colour). 95% confidence intervals are shown in parentheses.




Figure 1: Correlation between the albumin-creatinine ratio (ACR) and the estimated albumin excretion rate (eAER) in CARE FOR HOMe study participants.

Diskussion

Our findings underlines that eAER outperforms ACR as a predictor of CVE among patients with CKD G 2 - G 4.

We propose the substitution of eAER for ACR in clinical nephrology